Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets

YK Tham, BC Bernardo, JYY Ooi, KL Weeks… - Archives of …, 2015 - Springer
The onset of heart failure is typically preceded by cardiac hypertrophy, a response of the
heart to increased workload, a cardiac insult such as a heart attack or genetic mutation …

Molecular mechanisms of diabetic cardiomyopathy

H Bugger, ED Abel - Diabetologia, 2014 - Springer
In recent years, diabetes mellitus has become an epidemic and now represents one of the
most prevalent disorders. Cardiovascular complications are the major cause of mortality and …

Erasers of histone acetylation: the histone deacetylase enzymes

E Seto, M Yoshida - Cold Spring Harbor perspectives in …, 2014 - cshperspectives.cshlp.org
Histone deacetylases (HDACs) are enzymes that catalyze the removal of acetyl functional
groups from the lysine residues of both histone and nonhistone proteins. In humans, there …

Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies

BC Bernardo, KL Weeks, L Pretorius… - Pharmacology & …, 2010 - Elsevier
Cardiac hypertrophy can be defined as an increase in heart mass. Pathological cardiac
hypertrophy (heart growth that occurs in settings of disease, eg hypertension) is a key risk …

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

M Haberland, RL Montgomery, EN Olson - Nature Reviews Genetics, 2009 - nature.com
Histone deacetylases (HDACs) are part of a vast family of enzymes that have crucial roles in
numerous biological processes, largely through their repressive influence on transcription …

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs

HJ Kim, SC Bae - American journal of translational research, 2010 - pmc.ncbi.nlm.nih.gov
Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …

Physiological and pathological cardiac hypertrophy

I Shimizu, T Minamino - Journal of molecular and cellular cardiology, 2016 - Elsevier
The heart must continuously pump blood to supply the body with oxygen and nutrients. To
maintain the high energy consumption required by this role, the heart is equipped with …

Regulation of cardiac hypertrophy by intracellular signalling pathways

J Heineke, JD Molkentin - Nature reviews Molecular cell biology, 2006 - nature.com
The mammalian heart is a dynamic organ that can grow and change to accommodate
alterations in its workload. During development and in response to physiological stimuli or …

[PDF][PDF] HDAC and HDAC inhibitor: from cancer to cardiovascular diseases

S Yoon, GH Eom - Chonnam medical journal, 2016 - synapse.koreamed.org
Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail,
chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also …

HDAC family: What are the cancer relevant targets?

O Witt, HE Deubzer, T Milde, I Oehme - Cancer letters, 2009 - Elsevier
Histone deacetylases comprise a family of 18 genes, which are grouped into classes I–IV
based on their homology to their respective yeast orthologues. Classes I, II, and IV consist of …